| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2002; 41: 972-980
© 2002 British Society for Rheumatology
Review |
Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage
Department of Rheumatology, Hospital for Joint Diseases, New York University of Medicine, 301 East 17th Street, New York, NY 10003, USA
Destruction of articular joints occurs progressively in patients with rheumatoid arthritis (RA). Although the exact aetiology of RA has not been fully elucidated, a large body of evidence supports a role for interleukin-1 (IL-1) in cartilage and bone erosion. In vitro studies suggest that IL-1 can cause cartilage destruction by stimulating the release of matrix metalloproteinases and other degradative products, and it can increase bone resorption by stimulating osteoclast differentiation and activation. In animal models of RA, blocking the effects of IL-1 with either IL-1 receptor antagonist (IL-1Ra; endogenous), anti-IL-1 monoclonal antibodies, or soluble IL-1 type II receptors significantly reduced cartilage destruction and bone erosion. Gene therapy with IL-1Ra was also effective in reducing joint destruction in experimental RA and osteoarthritis (OA) models. In clinical studies, anakinra, a human recombinant IL-1 receptor antagonist (IL-1ra; exogenous), significantly slowed radiographic progression of RA relative to placebo and significantly reduced clinical symptoms when used as monotherapy or in addition to existing methotrexate therapy. These results demonstrate that blocking IL-1 protects bone and cartilage from progressive destruction in RA.
Correspondence to: S. B. Abramson.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. MERTENS and J. A. SINGH Anakinra for Rheumatoid Arthritis: A Systematic Review J Rheumatol, June 1, 2009; 36(6): 1118 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ahmad, J. Sylvester, M. Ahmad, and M. Zafarullah Adaptor Proteins and Ras Synergistically Regulate IL-1-Induced ADAMTS-4 Expression in Human Chondrocytes J. Immunol., April 15, 2009; 182(8): 5081 - 5087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Thomas, E. R. Edelman, and C. M. Stultz A BRIEF COMMUNICATION: Collagen Fragments Modulate Innate Immunity Experimental Biology and Medicine, March 1, 2007; 232(3): 406 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Murakami, H. Kohsaka, H. Kitasato, and T. Akahoshi Lipopolysaccharide-Induced Up-Regulation of Triggering Receptor Expressed on Myeloid Cells-1 Expression on Macrophages Is Regulated by Endogenous Prostaglandin E2 J. Immunol., January 15, 2007; 178(2): 1144 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ha, J.-H. Lee, H.-N. Kim, H.-M. Kim, H. B. Kwak, S. Lee, H.-H. Kim, and Z. H. Lee {alpha}-Lipoic Acid Inhibits Inflammatory Bone Resorption by Suppressing Prostaglandin E2 Synthesis J. Immunol., January 1, 2006; 176(1): 111 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Choe, B. Crain, S. R. Wu, and M. Corr Interleukin 1 Receptor Dependence of Serum Transferred Arthritis Can be Circumvented by Toll-like Receptor 4 Signaling J. Exp. Med., February 17, 2003; 197(4): 537 - 542. [Abstract] [Full Text] [PDF]
|
|